TIDMIXI

RNS Number : 2848U

IXICO plc

22 November 2019

22 November 2019

IXICO plc

("IXICO" or the "Company")

Notice of Results

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, will announce its final results for the year ended 30 September 2019 on Wednesday, 4 December 2019.

Giulio Cerroni, CEO and Grant Nash, CFO, will host a breakfast briefing and call for analysts at 09:00 GMT on the day of the results. Further details will be provided on request.

For further information please contact:

 
 IXICO plc                                        +44 (0) 20 3763 7498 
 Giulio Cerroni, Chief Executive Officer 
 
 Cenkos Securities PLC (Nominated adviser 
  and sole broker)                                +44 (0) 20 7397 8900 
 Giles Balleny / Max Gould (Corporate Finance) 
 Michael F Johnson / Russell Kerr (Sales) 
 
 Optimum Strategic Communications                  +44 (0) 203 950 9144 
 Mary Clark / Supriya Mathur / Manel Mateus 
 ixico@optimumcomms.com

About IXICO

IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and rare disease.

Our goal is to be a leading proponent in the use of AI in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience and rare disease, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.

More information is available on www.IXICO.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NORBRBDBUSDBGCB

(END) Dow Jones Newswires

November 22, 2019 02:00 ET (07:00 GMT)

Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Ixico Charts.
Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Ixico Charts.